((自动化翻译由路透提供，请见免责声明 ))
9月27日 - ** 分析师称，推迟削减医疗保险（Medicare）下某些实验室测试的报销比例将有助于Labcorp 和Quest Diagnostics 等美国实验室所有者实现2025年的利润和盈利
** LH股价上涨1.1%至222.73美元，DGX股价上涨近1%至155.51美元
** 美国国会周三将报销率的削减从2025年推迟到2026年
** 延迟符合预期，因为 LH 和 DGX 此前均表示可能会再次延迟"--摩根大通
** 摩根大通和杰富瑞（Jefferies）分析师均预计，在 25 财年，DGX 和 LH 的收入将分别增加约 8,500 万美元和约 8,000 万美元。
** 这也是公司利用部分暂时放弃的盈利削减重新投资改善业务运营、为并购提供资金或为股东创造价值的机会"--Jefferies。
** 包括盘中涨幅在内，LH 股价下跌 2.3%，DGX 股价年累计上涨 12.5
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.